Nomura Establishes Japanese Generics And Biotech Investment Funds
This article was originally published in PharmAsia News
Executive Summary
Japanese investment bank Nomura announced June 18 that it would establish investment funds containing a basket of generic drug makers and biotech companies June 24. Nomura Asset Management hopes to capitalize on current and future growth in the sectors. Japanese generic makers' share prices jumped on the news. Towa Pharmaceutical led the pack with ¥220 up for the day, marking a new high for the year. Saiwai Pharmaceutical's share price also increased by ¥170 to ¥5,270, also a new high for Japan's largest generic maker. Nichi-Iko shares rose for four days in a row. Another maker Fuji Pharmaceutical, however, saw shares drop by ¥18 due to heavy dependence on a single distributor. Since a diagnostic procedure combined payment system is expanding among hospitals in Japan, the generic drug market is expected to grow further. (Click here for more - Japanese languageYou may also be interested in...
Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Horizon's Teprotumumab Breezes Through US FDA Adcom, But Safety Questions Remain
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.
Need a specific report? 1000+ reports available
Buy Reports